Association between neoadjuvant paclitaxel dose intensity and outcomes in early triple-negative and HER2-positive breast cancer: a real-world data analysis
Reduction of PDI is frequently required during neoadjuvant treatment in early TNBC and HER2-positive BC, and is associated with lower pCR rate and IBCFS in TNBC. Reduction of PDI needs careful consideration, balancing adverse events and potential impact. Confirmation in independent datasets is warranted.
Authors
- Filipa Pereira (ORCID: https://orcid.org/0000-0001-9207-4856)
- G. Tramonti
- H. Yousuf (ORCID: https://orcid.org/0000-0001-9973-1927)
- Alexandra Thomas (ORCID: https://orcid.org/0000-0001-9022-2229)
- Michael Borges
- M. Vallet
- Michal Uher (ORCID: https://orcid.org/0000-0001-8970-5928)
- M.R. van Bockstal
- P. Vici
- F.P. Duhoux
- Lucas Diniz da Conceição (ORCID: https://orcid.org/0000-0002-2648-6809)
- Martine Berlière (ORCID: https://orcid.org/0000-0002-6472-9867)
- Eriseld Krasniqi (ORCID: https://orcid.org/0000-0002-6702-0087)
- Valeria Fano (ORCID: https://orcid.org/0000-0003-1396-4928)
- Gennaro Ciliberto (ORCID: https://orcid.org/0000-0003-2851-8605)
- Gaber Plavc (ORCID: https://orcid.org/0000-0002-9302-8066)
- Hayley Fenton (ORCID: https://orcid.org/0000-0001-7824-2614)
- Cédric van Marcke (ORCID: https://orcid.org/0000-0003-3454-0630)
- Kristin Pogoda
- K. Kolenc Mokotar
- Peter F. Hall
- Eve M. Dumas
- Anja Skoporc
Institutions
- Cliniques Universitaires Saint-Luc (BE)
- NHS Lothian (GB)
- Inserm (FR)
- Université Paris Cité (FR)
- Leeds Teaching Hospitals NHS Trust (GB)
- St James's University Hospital (GB)
- Edinburgh Cancer Research (GB)
- IQVIA (United Kingdom) (GB)
- Institute of Oncology Ljubljana (SI)
- Instituto Português de Oncologia Francisco Gentil (PT)
- Immunité et Cancer (FR)
- Masaryk Memorial Cancer Institute (CZ)
- The Maria Sklodowska-Curie National Research Institute of Oncology (PL)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
- Directorate-General Joint Research Centre (BE)
Publication Details
- Journal
- ESMO Real World Data and Digital Oncology
- Published
- 2025-06-19
- DOI
- https://doi.org/10.1016/j.esmorw.2025.100158
- Citations
- 1
- Primary Topic
- Breast Cancer Treatment Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.94